Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia
Nicola Cecchi1,2, Mariarita Sciumè2, Antony Ricchiuti1,2
1University of Milan, Milan, Italy.
Annals of Hematology
|May 15, 2025
Abstract
None:
Rituximab has never been investigated in MRD persistence/relapse. We describe a clinical picture of a woman with Ph-negative B-ALL CD20+, ineligible to allogeneic transplant, achieving MRD eradication using rituximab monotherapy after frontline chemotherapy and blinatumomab failure. This demonstrates rituximab's potential in MRD+ Ph-negative B-ALL CD20+, warranting further clinical investigation.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
